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ABSTRACT: Inspired by the preferential, allosteric binding of
RAPTA-T and auranoﬁn to the nucleosome core particle , we
describe the design and synthesis of a series of heterobimetallic
ruthenium(II)−gold(I) complexes with varying spacer lengths
ranging from four to eight polyethylene glycol units. Evaluation
of their cytotoxicity reveals IC50 values in the low micromolar
range against cisplatin sensitive and resistant human ovarian carcinoma (A2780, A2780cisR) and nontumoral human embryonic
kidney (HEK293) cell lines. Binding studies monitored via mass spectrometry revealed an aﬃnity for histidine residues on a
fragment of the amyloid β-protein (residues 1−16, employed as a model system), which is in accordance with the binding sites
of parent drugs, RAPTA-C and auranoﬁn, to the nucleosome core particle.
■ INTRODUCTION
Understanding and controlling the targets of metal-based drugs
remains of great importance in the development of selective
drugs.1,2 Ruthenium-based drugs possess a plethora of targets
ranging from proteins to DNA,3,4 and yet directing these
complexes toward a desirable target remains challenging. A
degree of control can be established in ruthenium(II)-arene
complexes by exchanging the bidentate ethylenediamine ligand
of [(η6-p-cymene)Ru (en)]PF6 (where en = ethylene diamine)
(RAED-C) for the compact, water-soluble PTA ligand of [(η6-
p-cymene)RuCl2(PTA)] (where PTA = 1,3,5-triaza-7-phos-
phaadamantane) (RAPTA-C, Figure 1), which directs the
complex preferentially toward histone protein binding sites on
the nucleosome over those of DNA.5 Furthermore, DNA
binding of RAED-C can be enhanced by substituting the p-
cymene arene with the more hydrophobic 5,8,9,10-tetrahy-
droanthracene (THA), resulting in the intercalation of DNA
and bimodal binding on naked DNA.6 On the other hand,
RAPTA-C and [Ru(η6-toluene)(PTA)Cl2] (RAPTA-T), which
diﬀer only by an iso-propyl group, form speciﬁc and identical
adducts on histone H2A and H2B histone dimers of the
nucleosome core.7 Notably, a series of binuclear ruthenium-
(II)-arene complexes are able to cross-link these binding sites,
inducing a state of irreversible condensed chromatin, resulting
in apoptosis.8 The binding of RAPTA-T9 at these sites,
consisting of two glutamic acid residues (RU1) and a glutamic
acid and histidine residue (RU2), causes a series of structural
changes in the nucleosome core that induces a kink in the long
α-helix of the H2A histone protein. This structural alteration
opens up a binding site for auranoﬁn, a gold(I) drug of the
structure (1-thio-β-D-glucopyranose-2,3,4,6-tetraacetato-S)-
(triethylphosphine)gold(I) (Figure 1), approved for the
treatment of rheumatoid arthritis,10 that is inaccessible prior
to the binding of the RAPTA-T. A synergy between the two
drugs was discovered where RAPTA-T appears to sensitize the
cells to auranoﬁn, resulting in a beneﬁcial increase in tumor
cell cytotoxicity and a threefold increase in auranoﬁn
chromatin adducts.11
Heterobimetallic complexes have emerged as a promising
family of complexes that can combine the attributes and targets
of two metals within one structure.12−18 As well as the capacity
to possess markedly higher activities than the parent drugs
alone,19 heterometallic drugs have a myriad of potential
applications. Numerous heterometallic complexes possessing
photophysical properties have been considered for cellular
imaging,20,21 as trackable probes,22,23 and as drug carriers for
cytotoxic complexes.24−26 Ferrocenyl and titanocene com-
plexes are particularly versatile building blocks for hetero-
metallic complexes due to their facile functionalization and
favorable redox properties27−34
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Figure 1. Parent drugs, RAPTA-C and auranoﬁn, and selected
heterobimetallic complexes.
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However, heterometallic complexes combining cisplatin-,
RAPTA-, and auranoﬁn-type drugs have been scarcely
explored. Ruthenium−gold and ruthenium−platinum species
have been shown to possess cytotoxicities comparable to
cisplatin against HeLa cells.35 A platinum(II)−gold(I) complex
was encapsulated within a ferritin cage with the aim of
enhancing its selectivity; however, the complex was unstable
with the gold(I) complex binding to the protein and platinum
remaining in the bulk, decreasing the eﬃcacy of the agent.36 A
ruthenium(II)−platinum(IV) prodrug possessing high cyto-
toxicity against cisplatin resistant cells was also able to inhibit
cell migration.37
The combination of RAPTA complexes, which possess a
general low toxicity and antimetastatic properties,2 and
auranoﬁn, which is highly cytotoxic with anti-inﬂammatory
properties,38 oﬀers great potential. Few heterometallic
complexes based on ruthenium(II)-arene compounds and
auranoﬁn have been reported. [(η6-p-Cymene)RuCl2(μ-
dppm)Au(IMes)]ClO4 (RANCE-1, Figure 1), where dppm =
diphenylphophanylmethyl(diphenyl) phosphane and IMes =
1,3-bis(2,4,6-trimethylphenyl)imidazole-2-ylidene), is a prom-
ising heterobimetallic complex exhibiting eﬃcient inhibition of
thioredoxin reductase (TrX), vascular endothelial growth
factor (VEGF), pan-matrix metalloproteinases (pan-MPP),
and pan-cathepsin. When compared to auranoﬁn, RANCE-1
presents similar antiproliferative activity against renal cancer
cell line (Caki-1) and improved inhibition of VEGF, pan-
MMP, and pan-cathepsin.39 Replacing the auranoﬁn-like
thiolato-β-D-glucose tetraacetate ligand with a chloride ligand
results in a threefold decrease in cytotoxicity against human
ovarian carcinoma (A2780) cells.40 Other examples include
[(η6-p-cymene)RuCl2(μ-dppm)AuCl] (RUAU-1, Figure 1)
and [(η6-p-cymene)RuCl2(μ-dppm)Au(S-thiazoline)], which
shows that diﬀering the sacriﬁcial ligand coordinated to the
gold center does not impact the activity in this case.41
However, introducing N-heterocyclic carbene ligands to the
gold center in cationic ruthenium(II)−gold(I) complexes of
the same structure can enhance tumor cell selectivity.42
Herein, we describe the synthesis, cytotoxicity, and target
binding studies of a series of heterobimetallic complexes
containing RAPTA-C− and auranoﬁn-like fragments. The
design of the complexes aims to preserve the structure of the
parent drugs, RAPTA-C and auranoﬁn, as closely as possible
while allowing ﬂexibility to enable binding at two diﬀerent and
distal sites. A series of linker lengths was explored to determine
the impact of the linker length on the cytotoxicity of the
complexes. The ability of the complexes to bind to histidine
residues was explored via mass spectrometry using both single
amino acids and a fragment of the amyloid β-protein.
■ RESULTS AND DISCUSSION
With the aim of targeting the binding sites of RAPTA-C and
auranoﬁn, maintaining the key structural features of the parent
drugs is important. However, alterations are required in order
to tether the complexes via a ﬂexible linker with the PTA and
triethylphosphine ligands, belonging to RAPTA-C and
au r anoﬁn , r e spec t i v e l y , b e ing r ep l a c ed by 4 -
(diphenylphosphosphino)benzoic acid ligands, which provide
a functionalizable carboxylic acid moiety and air stability. The
labile thio-β-D-glucose-2,3,4,6-tetraacetate ligand of auranoﬁn
is replaced with a labile chloride ligand. The p-cymene arene
and the two labile chloride ligands present in RAPTA-C were
maintained due to the hydrophobic interactions provided by
the arene during binding and the vital role of the chlorides in
the activation of the complex via aquation. Polyethylene glycol
was selected as a suitable linker due to its ﬂexibility and its
higher water solubility compared to that of alkyl chains.
As a 4-(diphenylphosphosphino)benzoic acid ligand is
coordinated to both the ruthenium(II) and the gold(I)
centers, care must be taken to achieve high selectivity in the
coupling step. Manipulation of reaction stoichiometry was
insuﬃcient to control the monocoordination of either
ruthenium or gold to a bis-phosphine ligand. Therefore,
monophosphine ligands (1a−1d) were prepared via the
es te r iﬁca t ion reac t ion be tween 1 equ iv o f 4 -
(diphenylphosphosphino)benzoic acid and 1.5 equiv of the
appropriate polyethylene glycol chain using N-ethyl-N′-(3-
dimethlaminopropyl)carbodiimide hydrochloride (EDCI) as
coupling reagent and 4-(dimethylamino)pyridine (DMAP) as
base catalyst (Scheme 1). Ligands 1a−1d (Scheme 1) were
coordinated to the gold via a freshly prepared gold(I)-
tetrahydrothiophene intermediate to yield gold(I) complexes
Scheme 1. Synthesis of Heterobimetallic Ruthenium(II)−Gold(I) Complexes, where n = 4 (a), 5 (b), 6 (c), and 8 (d)
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2a−2d in near-quantitative yields. The stability of the gold(I)-
phosphine complexes allows further reactions to take place
without eﬀecting the integrity of the complex. The second 4-
(diphenylphosphosphino)benzoic acid was introduced to the
gold complex using identical coupling conditions to those
employed in the ﬁrst synthetic step, resulting in cationic cyclic
gold complexes 3a−3d. The ﬁnal step introduces the
ruthenium(II) center via the coordination of one of the
phosphine ligands previously interacting with the gold(I)
center.
All compounds were characterized by 1H, 31P{1H}, and
13C{1H} NMR spectroscopy, high-resolution mass spectrom-
etry, and elemental analysis. The coordination of the ligands to
the metal centers was monitored by 31P{1H} NMR spectros-
copy. The phosphine ligand coordinated to the ruthenium
center produces a characteristic singlet at ca. 25 ppm, whereas
the gold-phosphine peak is observed at ca. 33 ppm (cf. ca. −5
ppm for the free ligand), allowing the reactions to be easily
mon i to r ed . The in t roduc t ion o f a s econd 4 -
(diphenylphosphosphino)benzoic acid to 2a−2d results in
changes of diﬀering magnitudes in the 31P{1H} NMR spectra,
depending on the number of PEG units the complex possesses.
The resulting cyclic gold(I) complexes 3a−3d present a single
broad peak at 29.53 (3a), 31.78 (3b), 28.20 (3c), and 31.09
(3d) ppm. The broad 31P{1H} NMR peaks observed for 3a−
3d can be attributed to the strain placed on the Au−P bonds
by the cyclization, leading to ﬂuctuations in the environment of
the phosphorus. Upon the introduction of the ruthenium(II)
center, 3a−3d decyclize, and two peaks are observed in the
31P{1H} NMR spectra, as mentioned above at ca. 25 and 33
ppm for the ruthenium(II) and gold(II) coordinated
phosphine ligands, respectively (Figure 2).
The 1H NMR spectra of the target complexes 4a−4d
conﬁrmed their formation with the appearance of the
distinctive p-cymene peaks including doublets at 5.20−5.22
and 4.97−4.99 ppm, septet at 2.80−2.88 ppm, singlet at 1.85−
1.86 ppm, and a doublet at 1.09−1.12 ppm. The coordination
of a phosphine ligand to the ruthenium was observed via a
downﬁeld shift of the (Ar)C−CH−CH−C−P−Ru phenyl
protons from 7.28 to 7.46 (3a−3d) to 7.77−7.83 ppm (4a−
4d) as well as the O−(CO)−(Ar)C−CH−CH−C−P−Ru
protons from 7.28 to 7.46 ppm (3a−3d) to 7.89−7.95 ppm
(4a−4d) (Figure 3).
In Vitro Antiproliferative Activity. The antiproliferative
activity of 4a−4d was assessed using the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay
against cisplatin sensitive and resistant human ovarian
carcinoma (A2780 and A2780cisR) and nontumoral human
embryonic kidney (HEK-293) cell lines (Table 1).43 Cisplatin,
auranoﬁn, and RAPTA-C were tested as controls.
The cytotoxicity of the parent complex, RAPTA-C, is low
against a range of cell lines, with an IC50 > 200 μM against the
tested cell lines. Compounds 4a−4d possess IC50 values in the
low micromolar range against all tested cell lines, with values
comparable to those of cisplatin and auranoﬁn against the
A2780 cell line and to auranoﬁn against the A2780 CisR cell
line. Although the compounds overcome cisplatin resistance,
they do not show selectivity toward the tumoral cell lines
compared to the nontumoral cell lines. Moreover, the length of
the PEG linker has negligible impact on the cytotoxicity of the
complexes, showing that the cytotoxicity of these complexes is
Figure 2. 31P{1H} NMR spectra (162 MHz, CDCl3) of the cyclic gold
complex 3b (top) and heterobimetallic complex 4b (bottom).
Figure 3. 1H NMR (400 MHz, CDCl3) spectra of cyclic gold complex
3b (top) and heterobimetallic complex 4b (bottom). Notable
resonances are identiﬁed with colored circles: phenyl protons (red),
η6-arene protons (blue), and PEG protons (green).
Table 1. In vitro Antiproliferative Activity of 4a−4d,
Cisplatin, Auranoﬁn, and RAPTA-C against Human Ovarian
Carcinoma (A2780), Human Ovarian Carcinoma Cisplatin
Resistant (A2780cisR), and Human Embryonic Kidney 293
(HEK-293) Cell Lines after 72 h Exposurea
compound A2780 A2780 CisR HEK293
4a 2.5 ± 0.3 3.1 ± 0.3 2.7 ± 0.1
4b 2.4 ± 0.5 3.1 ± 0.1 2.7 ± 0.1
4c 2.4 ± 0.3 3.6 ± 0.4 2.9 ± 0.3
4d 1.8 ± 0.6 3.9 ± 0.5 3.5 ± 0.4
cisplatin 1.9 ± 0.4 13.3 ± 1.2 9 ± 0.8
auranoﬁn44 1.3 ± 0.5 1.5 ± 0.5 1.9 ± 0.6
RAPTA-C >200 >200 >200
aValues are given as the mean ± SD (μM).
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independent of linker length, as observed with homobimetallic
ruthenium(II) and gold(I) complexes.44
Compounds 4a−4d are considerably more cytotoxic toward
the A2780 cell line compared to [(1-methyl-3-(4-((4′-methyl-
2,2′-bipyridin-4-yl)methylcarbamoyl)benzyl)imidazole-2-yli-
dine gold(I) chloride][(η6-p-cymene)ruthenium(II) chloride]
hexaﬂuorophosphate and [(1-methyl-3-(4-((4′-methyl-2,2′-
bipyridin-4-yl)methylcarbamoyl)benzyl)imidazole-2-ylidine
gold(I) (thiolato-β-D-glucose tetraacetate)][(η6-p-cymene)-
ruthenium(II) chloride] hexaﬂuoro-phosphate, which possess
IC50 values of 63.4 ± 2.4 and 16.8 ± 3.1 μM, respectively.
40
[(η6-p-Cymene)RuCl2(μ-dppm)Au(NHC)]ClO4 (where
NHC = N-heterocyclic carbene) complexes possess cytotox-
icity greater than that of cisplatin against human renal (Caki-1)
cells with IC50 values in the low micromolar range. They show
good selectivity toward nontumoral HEK-293 cells compared
to 4a−4d with IC50 values of ≥73 μM.42 The bimetallic
compounds [(η6-p-cymene)RuCl2(μ-dppm)AuCl] (RUAU-1,
Figure 1) and [(η6-p-cymene)RuCl2(μ-dppm)Au(S-thiazo-
line)] show comparable cytotoxicity toward human colon
(HCT-116) cells to the Ru(p-cymene)Cl2(μ-dppm)Au-
(NHC)]ClO4 complexes with IC50 values of 4.6 ± 0.1 μM
(1) and 6.5 ± 0.1 μM (2) versus 8−10 μM for the cationic
NHC complexes.41 RANCE-1 (Figure 1) also presents
comparable cytotoxicity to the cationic NHC complexes with
an IC50 of 8.7 ± 0.9 μM against Caki-1 cells, which is around
threefold more cytotoxic than cisplatin but threefold less
cytotoxic than auranoﬁn against the same cell line.39
Amino Acid and Peptide Binding Studies. The ability
of the heterobimetallic complexes to bind to the amino acid
residues present in the RU1, RU2, AU1, and AU1′ binding
sites in the nucleosome core particle was assessed using amino
acids and a model peptide. In crystallographic studies on the
nucleosome core particle, auranoﬁn binds to histidine residues
while RAPTA-T binds to both histidine and glutamine
residues.11 Complex 4b was incubated with L-histidine for 2
h in a 1:1 complex−amino acid ratio in unbuﬀered solution
(98% Milli-Q water, 2% DMSO) at 310 K, and the adducts
were analyzed by mass spectrometry.45−47 ESI-MS revealed a
peak at m/z 894.6949 corresponding to the adduct [4b − 3Cl
+ 3His + 2K]2+, in which dissociation of the three labile
chloride ligands and subsequent binding of three histidine
residues indicates that both the ruthenium and gold centers
bind to histidines.
Peptide binding studies were performed on a fragment of the
amyloid β-protein (residues 1−16, H-Asp1-Ala2-Glu3−
Phe4-Arg5-His6-Asp7-Ser8-Gly9-Tyr10-Glu11-Val12-His13-His14-
Gln15-Lys16−OH). Complex 4a was incubated with the 16-mer
for 2 h in a 1:3 complex−peptide ratio in unbuﬀered solution
(98% Milli-Q, 2% DMSO) at 310 K. A 1:3 complex−peptide
ratio was required to suppress the facile ionization of the gold
center that suppresses the signal of peptide complex adducts.
ESI-MS revealed 1:1 adducts of 4a and the 1−16 amyloid β-
peptide; 1:2 complex−peptides adducts were not observed
(Figure 4). The loss of the three labile chloride ligands in the
complex indicates that both the ruthenium and gold centers
are coordinated to at least one amino acid residue cross-linking
the peptide. Complex 4d, possessing the longest linker of the
series of PEG8, was incubated with the 1−16 amyloid β-
peptide under identical conditions. Similarly to 4a, 1:1
complex−peptide adducts were observed, while 1:2 com-
plex−peptide adducts were not found. To obtain further
information on the mode of binding in the 1:1 adduct
observed, the [peptide + 4a + 2H − 3Cl]5+ ion
(C140H179AuN27O35P2Ru
5+; theoretical m/z 631.8243; ob-
served m/z 631.8235; −1.16 ppm) (Figure S21) was chosen
for fragmentation due to its high charge state and intact 4a
adduct. Collision induced dissociation (CID), producing
predominantly b- and y-type fragments,48 and electron-transfer
dissociation (ETD) fragmentation, which breaks N−Cα bonds
along the peptide backbone producing c- and z-type frag-
ments,49 were performed. ETD fragmentation has recently
been used to evaluate the binding of dinuclear ruthenium(II)-
arene complexes on the amyloid β-peptide where the metal
centers were found to bind to histidine residues.50 The analysis
of the fragments produced was performed using an online
Apm2s application (available on http://www.cheminfo.org/
ﬂavor/mass/index.html),46,51 which enabled the identiﬁcation
of both terminal and internal fragments that are otherwise
diﬃcult to identify manually.
As both the ruthenium and gold centers can bind to
histidine, it is likely that the [peptide + 4a + 5H − 3Cl]5+ ion
represents a mixture of adducts in which the metals interact
with His6, His13, and His14 in diﬀerent combinations. The
unmetalated peptide fragments produced by the CID and ETD
fragmentation processes reveal an interesting pattern (Figure
5). The unmetalated CID fragments b6−b15 and y4−y15 were
observed, whereas the smaller fragments, y1−y3 and b1−b5,
were not present. The smallest fragments, b6 and y4, consist of
residues H-Asp1-Ala2-Glu3−Phe4-Arg5-His6 and His13-
His14-Gln15-Lys16−OH, respectively. In both directions, the
fragmentation process is interrupted at a histidine residue, His6
for b fragments and His13 for y fragments, suggesting that there
is obstruction, presumably a bound metal center, which
interrupts fragmentation. The ETD fragmentation reveals an
identical pattern where the unmetalated peptide fragments, c6,
c7, c9−c13, c15, and z4−z14 fragments, were observed (Figure 5).
The smallest fragments observed, c6 and z4, also consist of H-
Asp1-Ala2-Glu3-Phe4-Arg5-His6 and His13-His14-Gln15-Lys16−
OH, respectively. The similarity between the CID and ETD
fragmentation patterns suggest that the obstruction occurs at
His6 and His13, impeding both fragmentation processes.
Interestingly, the series of ETD peptide fragments
containing bound 4a (Figure 6) mirror the unmetalated
ETD fragments (Figure 5). The fragments c6*−c15* and z5*−
Figure 4. ESI-MS spectrum of 4a incubated with 1−16 amyloid β-
peptide in a 1:3 complex−peptide ratio at 310 K for 2 h (peaks of
interest are labeled).
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z15* containing the complete [4a − 3Cl] adduct are observed.
The smallest fragments, c6 and z5, consisting of H-Asp
1-Ala2-
Glu3-Phe4-Arg5-His6 and His13-His14-Gln15-Lys16−OH resi-
dues, respectively, are identical to the nonmetalated fragments.
Figure 5. Fragmentation of the [peptide + 4a + 2H − 3Cl]5+ ion (m/z 631.8235): unmetalated CID, b (blue) and y (purple), and ETD, c (red)
and z (green), fragments.
Figure 6. Fragmentation of the [peptide + 4a + 2H − 3Cl]5+ ion (m/z 631.8235): metalated CID, b (blue) and y (purple), and ETD, c (red) and z
(green), fragments containing the [4a − 3Cl] adduct.
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As it is plausible that both the gold and the ruthenium centers
could bind to any of the His6, His13, and His14 sites, a
ruthenium or gold center bound to the His6 and His13 residues
could be impeding further fragmentation of the peptide-4a
adduct. Metalated b- and y-type fragments containing [4a −
3Cl] are also observed in the CID spectrum (Figure 6);
however, the smallest fragments found are b11* and y12* and
do not yield much information.
However, the observed unmetalated internal fragments only
include one, if any, histidine residues. Fragments c13z8, c13z7
and c13z6 include the His
13 residue and the c7z13, c7z14, c7z15,
c9z12, c9z14, c10z15 and fragments include the His
6 residue. The
other unmetalated fragments observed internal fragments, c4z15
and c12z9, do not contain any histidines residues. This suggests
that the histidine residues that are not included in the
fragments could be bound to 4a.
In contrast, all the observed metalated CID and ETD
internal fragments containing the [4a −3Cl] adducts contain at
least one histidine residue (Figure 7). The CID internal
fragments b6y15* and b7y12*, contain Ala
2-Glu3-Phe4-Arg5-His6
and Arg5-His6-Asp7 residues, indicating that either the gold or
ruthenium centers are bound to the His6 residue. On the other
hand, the metalated internal ETD fragments include all three
histidine residues in diﬀerent combinations. Fragments c11z15*,
c11z13*, c10z15*, c10z14*, and c7z15* contain the His
6 residue;
c13z12* contains the His
13, and c15z7* contains both His
13 and
His14. Fragments c15z14*, c15z11*, and c14z11* contain all three
histidine residues His6, His13, and His14, suggesting that the
gold and ruthenium centers are both bound to the fragment via
at least one histidine.
Concluding Remarks. A series of heterometallic
ruthenium(II)−gold(I) complexes inspired by the preferential
binding of RAPTA-T and auranoﬁn in the nucleosome core
particle was synthesized with diﬀerent lengths of linkers
ranging from 4 to 8 PEG units. They possess cytotoxicities in
the low micromolar range against A2780, A2780cisR, and
HEK293 cell lines. Although they do not show selectivity
toward cancer cells, they do have the ability to overcome
cisplatin resistance in the A2780cisR cell line. Binding studies
performed on L-histidine and the 1−16 mer amyloid β-protein
show that the both the ruthenium and gold centers can bind to
histidine residues, suggesting that these complexes have the
capability to bind to the RU2, AU1, and AU1′ binding sites on
the nucleosome core particle.
■ EXPERIMENTAL SECTION
Materials. All commercially available starting materials were
purchased from Sigma-Aldrich, TCI, ABCR and used without further
puriﬁcation. Ruthenium trichloride hydrate was purchased from
precious metals online and used in the synthesis of the [Ru(p-
cymene)Cl2]2 dimer.
52
L-histidine was purchased from ABCR and the
1−16 β-amyloid peptide (H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-
Tyr-Glu-Val-His-His-Gln-Lys−OH) was purchased as a triﬂuoroace-
tate salt from Bachem. Dichloromethane was puriﬁed and degassed
using a PureSolv solvent puriﬁcation system (Innovative Technology
INC) prior to use. Reactions were monitored via thin-layer
chromatography carried out on silica plates (Merck 5554) and
visualized under UV radiation (254 nm). Flash column chromatog-
raphy was conducted in the normal phase on a CombiFlash-EZ prep
machine installed with prepacked Luknova columns and the stated
eluent system.
Instrumentation and Methods. 1H (400 MHz), 31P{1H} (101
MHz), and 13C{1H} (162 MHz) NMR spectra were conducted on a
Bruker Advance II 400 and referenced to the residual solvent peak of
CDCl3 (
1H: 7.26 ppm, 13C: 77.16 ppm). Coupling constants (J) are
reported in hertz. High-resolution ESI-MS characterization was
performed on a Xevo G2-S QTOF mass spectrometer coupled to
the Acquity UPLC Class Binary Solvent manager and BTN sample
manager (Waters, Corporation, Milford, MA). Elemental Analysis was
performed on a Thermo Scientiﬁc Flash 2000 organic elemental
analyzer.
S yn t h e s i s . Gen e r a l P r o c e d u r e o f 1a−1d . 4 -
(Diphenylphosphino)benzoic acid (1 equiv) and EDCI (1.3 equiv)
were dissolved in dry CH2Cl2 (3 mL) and stirred under N2 at room
temperature for 1 h. The solution was added dropwise to a solution of
the appropriate ethylene glycol (1.5 equiv) and DMAP (0.5 equiv) in
dry CH2Cl2 (2 mL), and the reaction was stirred under N2 at room
temperature for 21 h. The reaction mixture was washed with brine
(100 mL), dried over anhydrous sodium sulfate, ﬁltered and
concentrated under reduced pressure. Puriﬁcation was achieved via
ﬂash column chromatography using an eluent system of C6H14/
EtOAc and the product was isolated as a colorless oil.
Compound 1a. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.300 g, 0.979 mmol, 1 equiv),
EDCI (0.244 g, 1.273 mmol, 1.3 equiv), tetraethylene glycol (0.285 g,
Figure 7. Fragmentation of the [peptide + 4a + 2H − 3Cl]5+ ion (m/z 631.8235): metalated CID, bxyx (blue), and ETD, cxzx (red), internal
fragments containing the [4a − 3Cl] adduct.
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1.273 mmol,0.25 mL, 1.5 equiv), and DMAP (0.060 g, 0.490 mmol,
0.5 equiv) in CH2Cl2 (5 mL). The product was isolated as a colorless
oil (0.291 g, 0.603 mmol, 62%); Elemental Analysis (%): calcd for
C27H31O6P C 67.21 H 6.48; found C 67.20 H 6.42.
1H NMR (CDCl3,
400 MHz): 7.97−8.00 (2H, m, 2×O−(CO)−(Ar)C−CH−CH−
C−P), 7.26−7.38 (12H, m, 2×O−(CO)−(Ar)C−CH−CH−C−P,
4×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−CH−CH−CH, 2×P−
(Ar)C−CH−CH−CH), 4.46−4.49 (2H, m, Ar−(CO)−O−
CH2−CH2−O), 3.80−3.83 (2H, m, Ar−(CO)−O−CH2−CH2−
O), 3.60−3.71 (10H, m, Ar−(CO)−O−(CH2)2−O−(CH2)2, Ar−
(CO)−O−((CH2)2−O)2−(CH2)2, Ar−(CO)−O−((CH2)2−
O)3−CH2−CH2−OH), 3.57−3.60 (2H, m, Ar−(CO)−O−
((CH2)2−O)3−CH2−CH2−OH); 31P {1H} NMR (CDCl3, 162
MHz): −4.95 (1P); 13C {1H} NMR (CDCl3, 101 MHz): 166.4
(1C, O−(CO)−(Ar)C−CH−CH−C−P), 144.3 (1C, d, O−(C
O)−(Ar)C−CH−CH−C−P, 1JC,P = 14 Hz), 136.3 (2C, d, 2×P−
(Ar)C−CH−CH−CH, 1JC,P = 11 Hz), 134.1 (4C, d, 4×P−(Ar)C−
CH−CH−CH, 2JC,P = 20 Hz), 133.3 (2C, d, 2×O−(CO)−(Ar)C−
CH−CH−C−P, 2JC,P = 19 Hz), 130.1 (1C, O−(CO)−(Ar)C−
CH−CH−C−P), 129.5 (2C, d, 2×O−(CO)−(Ar)C−CH−CH−
C−P, 3JC,P = 6 Hz), 129.2 (2C, 2×P−(Ar)C−CH−CH−CH), 128.8
(4C, d, 4×P−(Ar)C−CH−CH−CH, 3JC,P = 7 Hz), 72.6 (1C, O−
CH2−CH2−OH), 70.8 (2C, Ar−(CO)−O−((CH2)2−O)2-CH2,
Ar−(CO)−O−(CH2)2−O−CH2-CH2), 70.7 (1C, Ar−(CO)−
O−((CH2)2−O)2−CH2−CH2), 70.5 (1C, Ar−(CO)−O−
(CH2)2−O−CH2), 69.3 (1C, (Ar)−(CO)−O−CH2−CH2−O),
64.2 (1C, (Ar)−(CO)−O−CH2−CH2−O), 61.9 (1C, O−CH2−
CH2−OH), 2.19 (1H, bs, −OH); HRMS (ESI(+)-QTOF): m/z
found 483.1938 [M + H]+ C27H32O6P
+ requires 483.1931 (ppm =
1.45), 505.1768 [M + Na]+ C27H31O6PNa requires 505.1750 (ppm =
3.56).
Compound 1b. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.300 g, 0.979 mmol, 1 equiv),
EDCI (0.244 g, 1.273 mmol, 1.3 equiv), pentaethylene glycol (0.350
g, 1.469 mmol, 0.31 mL, 1.5 equiv), and DMAP (0.060 g, 0.490
mmol, 0.5 equiv) in CH2Cl2 (5 mL). The product was isolated as a
colorless oil (0.340 g, 0.646 mmol, 66%); Elemental Analysis (%):
calcd For C29H35O7P C 66.15 H 6.70; found C 66.02 H 6.66;
1H
NMR (CDCl3, 400 MHz): 7.97−8.00 (2H, m, 2×O−(CO)−
(Ar)C−CH−CH−C−P), 7.26−7.38 (12H, m, 2×O−(CO)−
(Ar)C−CH−CH−C−P, 4×P−(Ar)C−CH−CH−CH, 4×P−
(Ar)C−CH−CH−CH, 2×P−(Ar)C−CH−CH−CH), 4.45−4.48
(2H, m, Ar−(CO)−O−CH2−CH2−O), 3.80−3.83 (2H, m, Ar−
(CO)−O−CH2−CH2−O), 3.60−3.71 (16H, m, Ar−(CO)−O−
(CH2)2−O−(CH2)2, Ar−(CO)−O−((CH2)2−O)2−(CH2)2, Ar−
(CO)−O−((CH2)2−O)3−(CH2)2, Ar−(CO)−O−((CH2)2−
O)4−(CH2)2−OH, 2.19 (1H, bs, −OH); 31P {1H} NMR (CDCl3,
162 MHz): −5.05 (1P); 13C {1H} NMR (CDCl3, 101 MHz): 166.5
(1C, O−(CO)−(Ar)C−CH−CH−C−P), 144.3 (1C, d, O−(C
O)−(Ar)C−CH−CH−C−P, 1JC,P = 14 Hz), 136.3 (2C, d, 2×P−
(Ar)C−CH−CH−CH, 1JC,P = 11 Hz), 134.1 (4C, d, 4×P−(Ar)C−
CH−CH−CH, 2JC,P = 20 Hz), 133.3 (2C, d, 2×O−(CO)−(Ar)C−
CH−CH−C−P, 2JC,P = 19 Hz), 130.2 (1C, O−(CO)−(Ar)C−
CH−CH−C−P), 129.5 (2C, d, 2×O−(CO)−(Ar)C−CH−CH−
C−P, 3JC,P = 6 Hz), 129.3 (2C, 2×P−(Ar)C−CH−CH−CH), 128.8
(4C, d, 4×P−(Ar)C−CH−CH−CH, 3JC,P = 7 Hz), 72.6 (1C, O−
CH2−CH2−OH), 70.7−70.8 (5C, Ar−(CO)−O−(CH2)2−O−
CH2− CH2, Ar−(CO)−O−((CH2)2−O)2−(CH2)2, Ar−(C
O)−O−((CH2)2−O)3−(CH2)2), 70.5 (1C, Ar−(CO)−O−
(CH2)2−O−CH2), 69.3 (1C, (Ar)−(CO)−O−CH2−CH2−O),
64.2 (1C, (Ar)−(CO)−O−CH2−CH2−O), 61.9 (1C, O−CH2−
CH2−OH); HRMS (ESI(+)-QTOF): m/z found 527.2198 [M + H]+
C29H36O7P
+ requires 527.2193 (ppm = 0.95), 549.2040 [M + Na]+
C29H35O7PNa requires 549.2013 (ppm = 4.92).
Compound 1c. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.300 g, 0.979 mmol, 1 equiv),
EDCI (0.244 g, 1.273 mmol, 1.3 equiv), hexaethylene glycol (0.414 g,
1.469 mmol, 0.37 mL, 1.5 equiv), and DMAP (0.060 g, 0.490 mmol,
0.5 equiv) in CH2Cl2 (5 mL). The product was isolated as a colorless
oil (0.372 g, 0.652 mmol, 67%); Elemental Analysis (%): calcd for
C31H39O8P C 65.25 H 6.89; found C 65.16 H 6.93;
1H NMR (CDCl3,
400 MHz): 7.97−7.99 (2H, m, 2×O−(CO)−(Ar)C−CH−CH−
C−P), 7.29−7.38 (12H, m, 2×O−(CO)−(Ar)C−CH−CH−C−P,
4×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−CH−CH−CH, 2×P−
(Ar)C−CH−CH−CH), 4.45−4.47 (2H, m, Ar−(CO)−O−
CH2−CH2−O), 3.80−3.83 (2H, m, Ar−(CO)−O−CH2−CH2−
O), 3.58−3.72 (20H, m, Ar−(CO)−O−(CH2)2−O−(CH2)2, Ar−
(CO)−O−((CH2)2−O)2−(CH2)2, Ar−(CO)−O−((CH2)2−
O)3−(CH2)2, Ar−(CO)−O−((CH2)2−O)5−(CH2)2, Ar−(C
O)−O−((CH2)2−O)5−(CH2)2−OH, 2.65 (1H, bs, −OH); 31P
{1H} NMR (CDCl3, 162 MHz): −4.84 (1P); 13C {1H} NMR
(CDCl3, 101 MHz): 166.4 (1C, O−(CO)−(Ar)C−CH−CH−C−
P), 144.3 (1C, d, O−(CO)−(Ar)C−CH−CH−C−P, 1JC,P = 14
Hz), 136.3 (2C, d, 2×P−(Ar)C−CH−CH−CH, 1JC,P = 11 Hz), 134.1
(4C, d, 4×P−(Ar)C−CH−CH−CH, 2JC,P = 20 Hz), 133.3 (2C, d,
2×O−(CO)−(Ar)C−CH−CH−C−P, 2JC,P = 19 Hz), 130.2 (1C,
O−(CO)−(Ar)C−CH−CH−C−P), 129.5 (2C, d, 2×O−(C
O)−(Ar)C−CH−CH−C−P, 3JC,P = 6 Hz), 129.3 (2C, 2×P−(Ar)C−
CH−CH−CH), 128.8 (4C, d, 4×P−(Ar)C−CH−CH−CH, 3JC,P = 7
Hz), 72.7 (1C, O−CH2−CH2−OH), 70.7−70.8 (7C, Ar−(CO)−
O−(CH2)2−O−CH2-CH2, Ar−(CO)−O−((CH2)2−O)2−(CH2)2,
Ar−(CO)−O−((CH2)2−O)3−(CH2)2, Ar−(CO)−O−
((CH2)4−O)2−(CH2)2), 70.5 (1C, Ar−(CO)−O−(CH2)2−O−
CH2), 69.3 (1C, (Ar)−(CO)−O−CH2−CH2−O), 64.3 (1C,
(Ar)−(CO)−O−CH2−CH2−O), 61.9 (1C, O−CH2−CH2−
OH); HRMS (ESI(+)-QTOF): m/z found 571.2467 [M + H]+
C31H40O8P
+ requires 571.2461 (ppm = 1.05).
Compound 1d. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.300 g, 0.979 mmol, 1 equiv),
EDCI (0.244 g, 1.273 mmol, 1.3 equiv), octaethylene glycol (0.544 g,
1.469 mmol, 1.5 equiv), and DMAP (0.060 g, 0.490 mmol, 0.5 equiv)
in CH2Cl2 (5 mL). The product was isolated as a colorless oil (0.309
g, 0.469 mmol, 48%); Elemental Analysis (%): calcd for C35H47O10P·
C6H14 C 66.11 H 8.25, found C 66.31 H 8.02;
1H NMR (CDCl3, 400
MHz): 7.96−7.98 (2H, m, 2×O−(CO)−(Ar)C−CH−CH−C−P),
7.30−7.36 (12H, m, 2×O−(CO)−(Ar)C−CH−CH−C−P, 4×P−
(Ar)C−CH−CH−CH, 4×P−(Ar)C−CH−CH−CH, 2×P−(Ar)C−
CH−CH−CH), 4.44−4.46 (2H, m, Ar−(CO)−O−CH2−CH2−
O), 3.79−3.82 (2H, m, Ar−(CO)−O−CH2−CH2−O), 3.58−3.72
(28H, m, Ar−(CO)−O−(CH2)2−O−(CH2)2, Ar−(CO)−O−
((CH2)2−O)2−O−(CH2)2, Ar−(CO)−O−((CH2)2−O)3−
(CH2)2, Ar−(CO)−O−((CH2)2−O)4−(CH2)2, Ar−(CO)−
O−((CH2)2−O)5−(CH2)2, Ar−(CO)−O−((CH2)2−O)6−
(CH2)2, Ar−(CO)−O−((CH2)2−O)7−(CH2)2−OH); 31P {1H}
NMR (CDCl3, 162 MHz): −5.08 (1P); 13C {1H} NMR (CDCl3, 101
MHz): 166.4 (1C, O−(CO)−(Ar)C−CH−CH−C−P), 143.2
(1C, d, O−(CO)−(Ar)C−CH−CH−C−P, 1JC,P = 14 Hz), 135.2
(2C, d, 2×P−(Ar)C−CH−CH−CH, 1JC,P = 11 Hz), 133.0 (4C, d,
4×P−(Ar)C−CH−CH−CH, 2JC,P = 20 Hz), 132.2 (2C, d, 2×O−
(CO)−(Ar)C−CH−CH−C−P, 2JC,P = 19 Hz), 129.1 (1C, O−
(CO)−(Ar)C−CH−CH−C−P), 128.5 (2C, d, 2×O−(CO)−
(Ar)C−CH−CH−C−P, 3JC,P = 6 Hz), 128.2 (2C, 2×P−(Ar)C−
CH−CH−CH), 127.4 (4C, d, 4×P−(Ar)C−CH−CH−CH, 3JC,P = 7
Hz), 71.6 (1C, O−CH2−CH2−OH), 69.41−69.77 (12C, Ar−(C
O)−O−(CH2)2−O−(CH2)2, Ar−(CO)−O−((CH2)2−O)2−O−
(CH2)2, Ar−(CO)−O−((CH2)2−O)3−(CH2)2, Ar−(CO)−
O−((CH2)2−O)4−(CH2)2, Ar−(CO)−O−((CH2)2−O)5−
(CH2)2, Ar−(CO)−O−((CH2)6−O)2−(CH2)2), 68.3 (1C, (Ar)−
(CO)−O−CH2−CH2−O), 63.3 (1C, (Ar)−(CO)−O−CH2−
CH2−O), 60.8 (1C, CH2−CH2−OH); HRMS (ESI(+)-QTOF): m/z
found 681.2808 [M + Na]+ C35H47O10PNa
+ requires 681.2805 (ppm
= 0.44).
General Procedure of 2a−2d. The appropriate monophosphine
ligand (1 equiv) and freshly prepared AuCl(tht)53 (1 equiv) were
dissolved in CH2Cl2 (10 mL) and stirred under N2 and rt for 18 h.
The reaction mixture was concentrated to 1 mL under reduced
pressure and was puriﬁed via ﬂash column chromatography using
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CH2Cl2/CH3OH as eluent. The product was isolated as a colorless
oil.
Compound 2a. According to the general procedure, 1a (0.291 g,
0.603 mmol, 1 equiv) and AuCl(tht) (0.193 g, 0.603 mmol, 1 equiv)
in CH2Cl2 (10 mL). The product was isolated as a colorless oil (0.419
g, 0.587 mmol, 97%); Elemental Analysis (%): calcd for
C27H31AuClO9P C 45.36 H 4.37; found C 45.71 H 4.57;
1H NMR
(CDCl3, 400 MHz): 8.02−8.04 (2H, m, 2×O−(CO)−(Ar)C−
CH−CH−C−P), 7.38−7.51 (12H, m, 2×O−(CO)−(Ar)C−CH−
CH−C−P, 4×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−CH−CH−
CH, 2×P−(Ar)C−CH−CH−CH), 4.38−4.40 (2H m, Ar−(C
O)−O−CH2−CH2−O), 3.72−3.74 (2H, m, Ar−(CO)−O−CH2−
CH2−O), 3.54−3.59 (10H, m, Ar−(CO)−O−(CH2)2−O−
(CH2)2, Ar−(CO)−O−((CH2)2−O)2−(CH2)2, Ar−(CO)−
O−((CH2)2−O)3-CH2), 3.45−3.47 (2H, m, O−CH2−CH2−OH);
31P {1H} NMR (CDCl3, 162 MHz): 32.89 (1P);
13C {1H} NMR
(CDCl3, 101 MHz): 165.1 (1C, O−(CO)−(Ar)C−CH−CH−C−
P), 134.0 (1C, d, O−(CO)−(Ar)C−CH−CH−C−P, 1JC,P = 60
Hz), 133.9 (4C, d, 4×P−(Ar)C−CH−CH−CH, 2JC,P = 14 Hz), 133.7
(2C, d, 2×O−(CO)−(Ar)C−CH−CH−C−P, 2JC,P = 14 Hz),
133.0 (1C, O−(CO)−(Ar)C−CH−CH−C−P, 4JC,P = 3 Hz),
132.2 (2C, 2×P−(Ar)C−CH−CH−CH, 4JC,P = 3 Hz), 129.9 (2C, d,
2×O−(CO)−(Ar)C−CH−CH−C−P, 3JC,P = 12 Hz), 129.3 (4C,
4×P−(Ar)C−CH−CH−CH, 3JC,P = 12 Hz), 127.5 (2C, d, 2×P−
(Ar)C−CH−CH−CH, 1JC,P = 63 Hz), 72.3 (1C, O−CH2−CH2−
OH), 70.2−70.4 (3C, Ar−(CO)−O−(CH2)2−O−CH2-CH2, Ar−
(CO)−O−((CH2)2−O)2−(CH2)2), 70.0 (1C, Ar−(CO)−O−
(CH2)2−O−CH2), 68.8 (1C, Ar−(CO)−O−CH2−CH2), 64.4
(1C, Ar−(CO)−O−CH2−CH2), 61.3 (1C, O−CH2−CH2−OH);
HRMS (ESI(+)-QTOF): m/z found 737.1116 [M + Na]+
C27H31AuClO6PNa
+ requires 737.1110 (ppm = 0.81).
Compound 2b. According to the general procedure, 1b (0.340 g,
0.646 mmol, 1 equiv) and AuCl(tht) (0.207 g, 0.646 mmol, 1 equiv)
in CH2Cl2 (10 mL). The product was isolated as a colorless oil (0.482
g, 0.634 mmol, 98%); Elemental Analysis (%): calcd for
C29H35AuClO7P C 45.89 H 4.65; found C 45.49 H 4.63;
1H NMR
(CDCl3, 400 MHz): 8.08−8.11 (2H, m, 2×O−(CO)−(Ar)C−
CH−CH−C−P), 7.46−7.58 (12H, m, 2×O−(CO)−(Ar)C−CH−
CH−C−P, 4×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−CH−CH−
CH, 2×P−(Ar)C−CH−CH−CH), 4.45−4.48 (2H m, Ar−(C
O)−O−CH2−CH2−O), 3.79−3.81 (2H, m, Ar−(CO)−O−CH2−
CH2−O), 3.58−3.68 (14H, m, Ar−(CO)−O−(CH2)2−O−
(CH2)2, Ar−(CO)−O−((CH2)2−O)2−(CH2)2, Ar−(CO)−
O−((CH2)2−O)3−(CH2)2, Ar−(CO)−O−((CH2)2−O)4-CH2),
3.54−3.57 (2H, m, O−CH2−CH2−OH); 31P {1H} NMR (CDCl3,
162 MHz): 33.00 (1P); 13C {1H} NMR (CDCl3, 101 MHz): 165.3
(1C, O−(CO)−(Ar)C−CH−CH−C−P), 134.3 (1C, d, O−(C
O)−(Ar)C−CH−CH−C−P, 1JC,P = 60 Hz), 134.2 (4C, d, 4×P−
(Ar)C−CH−CH−CH, 2JC,P = 14 Hz), 133.9 (2C, d, 2×O−(CO)−
(Ar)C−CH−CH−C−P, 2JC,P = 14 Hz), 133.3 (1C, O−(CO)−
(Ar)C−CH−CH−C−P, 4JC,P = 3 Hz), 132.4 (2C, 2×P−(Ar)C−
CH−CH−CH, 4JC,P = 3 Hz), 130.2 (2C, d, 2×O−(CO)−(Ar)C−
CH−CH−C−P, 3JC,P = 12 Hz), 129.3 (4C, 4×P−(Ar)C−CH−CH−
CH, 3JC,P = 12 Hz), 127.9 (2C, d, 2×P−(Ar)C−CH−CH−CH, 1JC,P
= 63 Hz), 72.5 (1C, O−CH2−CH2−OH), 70.5−70.7 (5C, Ar−(C
O)−O−(CH2)2−O−CH2-CH2, Ar−(CO)−O−((CH2)2−O)2−
(CH2)2, Ar−(CO)−O−((CH2)2−O)3−(CH2)2), 70.3 (1C, Ar−
(CO)−O−(CH2)2−O−CH2), 69.1 (1C, Ar−(CO)−O−CH2−
CH2), 64.7 (1C, Ar−(CO)−O−CH2−CH2), 61.7 (1C, O−CH2−
CH2−OH); HRMS (ESI(+)-QTOF): m/z found 781.1393 [M +
Na]+ C29H35AuClO7PNa
+ requires 781.1372 (ppm = 2.69).
Compound 2c. According to the general procedure, 1c (0.370 g,
0.652 mmol, 1 equiv) and AuCl(tht) (0.209 g, 0.652 mmol, 1 equiv)
in CH2Cl2 (10 mL). The product was isolated as a colorless oil (0.503
g, 0.503 mmol, 96%); Elemental Analysis (%): calcd for
C31H39AuClO8P C 46.37 H 4.90; found C 46.25 H 4.69;
1H NMR
(CDCl3, 400 MHz): 8.03−8.11 (2H, m, 2×O−(CO)−(Ar)C−
CH−CH−C−P), 7.45−7.57 (12H, m, 2×O−(CO)−(Ar)C−CH−
CH−C−P, 4×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−CH−CH−
CH, 2×P−(Ar)C−CH−CH−CH), 4.45−4.47 (2H m, Ar−(C
O)−O−CH2−CH2−O), 3.78−3.81 (2H, m, Ar−(CO)−O−CH2−
CH2−O), 3.53−3.67 (20H, m, Ar−(CO)−O−(CH2)2−O−
(CH2)2, Ar−(CO)−O−((CH2)2−O)2−(CH2)2, Ar−(CO)−
O−((CH2)2−O)3−(CH2)2, Ar−(CO)−O−((CH2)2−O)4−
(CH2)2, Ar−(CO)−O−((CH2)2−O)5−(CH2)2−OH); 31P {1H}
NMR (CDCl3, 162 MHz): 32.98 (1P);
13C {1H} NMR (CDCl3, 101
MHz): 165.4 (1C, O−(CO)−(Ar)C−CH−CH−C−P), 134.2
(1C, d, O−(CO)−(Ar)C−CH−CH−C−P, 1JC,P = 60 Hz), 134.2
(4C, d, 4×P−(Ar)C−CH−CH−CH, 2JC,P = 14 Hz), 133.9 (2C, d,
2×O−(CO)−(Ar)C−CH−CH−C−P, 2JC,P = 14 Hz), 133.3 (1C,
O−(CO)−(Ar)C−CH−CH−C−P, 4JC,P = 3 Hz), 132.4 (2C,
2×P−(Ar)C−CH−CH−CH, 4JC,P = 3 Hz), 130.2 (2C, d, 2×O−
(CO)−(Ar)C−CH−CH−C−P, 3JC,P = 12 Hz), 129.5 (4C, 4×P−
(Ar)C−CH−CH−CH, 3JC,P = 12 Hz), 127.9 (2C, d, 2×P−(Ar)C−
CH−CH−CH, 1JC,P = 63 Hz), 72.7 (1C, O−CH2−CH2−OH), 70.4−
70.6 (7C, Ar−(CO)−O−(CH2)2−O−CH2-CH2, Ar−(CO)−
O−((CH2)2−O)2−(CH2)2, Ar−(CO)−O−((CH2)2−O)3−
(CH2)2, Ar−(CO)−O−((CH2)2−O)4−(CH2)2), 70.1 (1C, Ar−
(CO)−O−(CH2)2−O−CH2), 69.1 (1C, Ar−(CO)−O−CH2−
CH2), 64.7 (1C, Ar−(CO)−O−CH2−CH2), 61.6 (1C, O−CH2−
CH2−OH); HRMS (ESI(+)-QTOF): m/z found 825.1644 [M +
Na]+ C31H39AuClO8PNa
+ requires 825.1635 (ppm = 1.09).
Compound 2d. According to the general procedure, 1d (0.309 g,
0.469 mmol, 1 equiv) and AuCl(tht) (0.150 g, 0.469 mmol, 1 equiv)
in CH2Cl2 (10 mL). The product was isolated as a colorless oil (0.411
g, 0.461 mmol, 98%); Elemental Analysis (%): calcd for
C35H47AuClO10P C 47.17 H 5.32; found C 47.06 H 5.39;
1H NMR
(CDCl3, 400 MHz): 8.05−8.07 (2H, m, 2×O−(CO)−(Ar)C−
CH−CH−C−P), 7.44−7.54 (12H, m, 2×O−(CO)−(Ar)C−CH−
CH−C−P, 4×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−CH−CH−
CH, 2×P−(Ar)C−CH−CH−CH), 4.42−4.44 (2H m, Ar−(C
O)−O−CH2−CH2−O), 3.76−3.78 (2H, m, Ar−(CO)−O−CH2−
CH2−O), 3.52−3.66 (28H, m, Ar−(CO)−O−(CH2)2−O−
(CH2)2, Ar−(CO)−O−((CH2)2−O)2−(CH2)2, Ar−(CO)−
O−((CH2)2−O)3−(CH2)2, Ar−(CO)−O−((CH2)2−O)4−
(CH2)2, Ar−(CO)−O−((CH2)2−O)5−(CH2)2, Ar−(CO)−
O−((CH2)2−O)6−(CH2)2, Ar−(CO)−O−((CH2)2−O)7−
(CH2)2);
31P {1H} NMR (CDCl3, 162 MHz): 32.95 (1P);
13C
{1H} NMR (CDCl3, 101 MHz): 165.2 (1C, O−(CO)−(Ar)C−
CH−CH−C−P), 134.1 (1C, d, O−(CO)−(Ar)C−CH−CH−C−
P, 1JC,P = 60 Hz), 134.1 (4C, d, 4×P−(Ar)C−CH−CH−CH, 2JC,P =
14 Hz), 133.8 (2C, d, 2×O−(CO)−(Ar)C−CH−CH−C−P, 2JC,P
= 14 Hz), 133.1 (1C, O−(CO)−(Ar)C−CH−CH−C−P, 4JC,P = 3
Hz), 132.3 (2C, 2×P−(Ar)C−CH−CH−CH, 4JC,P = 3 Hz), 130.0
(2C, d, 2×O−(CO)−(Ar)C−CH−CH−C−P, 3JC,P = 12 Hz),
129.3 (4C, 4×P−(Ar)C−CH−CH−CH, 3JC,P = 12 Hz), 127.7 (2C, d,
2×P−(Ar)C−CH−CH−CH, 1JC,P = 63 Hz), 72.4 (1C, O−CH2−
CH2−OH), 70.4−70.5 (11C, Ar−(CO)−O−(CH2)2−O−CH2-
CH2, Ar−(CO)−O−((CH2)2−O)2−(CH2)2, Ar−(CO)−O−
((CH2)2−O)3−(CH2)2, Ar−(CO)−O−((CH2)2−O)4−(CH2)2,
Ar−(CO)−O−((CH2)2−O)5−(CH2)2, Ar−(CO)−O−
((CH2)2−O)6−(CH2)2), 70.1 (1C, Ar−(CO)−O−(CH2)2−O−
CH2), 68.9 (1C, Ar−(CO)−O−CH2−CH2), 64.6 (1C, Ar−(C
O)−O−CH2−CH2), 61.5 (1C, O−CH2−CH2−OH); HRMS (ESI-
(+)-QTOF): m/z found 913.2172 [M + Na]+ C35H47AuClO10PNa
+
requires 913.2159 (ppm = 1.42).
General Procedure for 3a−3d. 4-(Diphenylphosphino)benzoic
acid (1.2 equiv) and EDCI (1.5 equiv) were dissolved in dry CH2Cl2
(2 mL) and stirred under N2 at room temperature for 1 h. The
solution was added to a solution of the appropriate monophosphine
gold(I) complex (1 equiv) and DMAP (0.5 equiv) in dry CH2Cl2 (3
mL), and the reaction mixture was stirred under N2 at room
temperature for 20 h. The reaction mixture was washed with brine (40
mL), dried over anhydrous sodium sulfate, ﬁltered, and concentrated
under reduced pressure. Puriﬁcation was achieved via ﬂash column
chromatography using an eluent system of CH2Cl2/CH3OH. The
product was washed with pentane (3 × 25 mL) and isolated as a
cream oil.
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Compound 3a. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.097 g, 0.317 mmol, 1.2 equiv),
EDCI (0.097 g, 0.397 mmol, 1.5 equiv), 2a (0.189 g, 0.264 mmol, 1
equiv) and DMAP (0.016 g, 0.132 mmol, 0.5 equiv) in CH2Cl2 (5
mL). The product was isolated as a cream oil (0.220 g, 0.219 mmol,
83%); Elemental Analysis (%): calcd for C46H44AuClO7P2.
1/2CH2Cl2
C 53.41 H 4.34; found C 53.07 H 4.46; 1H NMR (CDCl3, 400 MHz):
7.87−7.89 (4H, m, 4×O−(CO)−(Ar)C−CH−CH−C−P), 7.28−
7.43 (24H, m, 4×O−(CO)−(Ar)C−CH−CH−C−P, 8×P−
(Ar)C−CH−CH−CH, 8×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−
CH−CH−CH), 5.29 (s, residual CH2Cl2), 4.43−4.46 (4H m, Ar−
(CO)−O−CH2−CH2−O), 3.79−3.82 (4H, m, Ar−(CO)−O−
CH2−CH2−O), 3.66−3.68 (8H, m, 2×Ar−(CO)−O−(CH2)2−
O−(CH2)2); 31P {1H} NMR (CDCl3, 162 MHz): 29.53 (1P); 13C
{1H} NMR (CDCl3, 101 MHz): 165.8 (2C, 2×O−(CO)−(Ar)C−
CH−CH−C−P), 138.6 (2C, d, 2×O−(CO)−(Ar)C−CH−CH−
C−P, 1JC,P = 33 Hz), 134.1 (8C, 8×P−(Ar)C−CH−CH−CH), 133.5
(4C, 4×O−(CO)−(Ar)C−CH−CH−C−P), 131.8 (2C, 2×O−
(CO)−(Ar)C−CH−CH−C−P), 131.5 (4C, d, 4×P−(Ar)C−
CH−CH−CH, 1JC,P = 38 Hz), 131.0 (4C, 4×P−(Ar)C−CH−CH−
CH), 129.7 (4C, 4×O−(CO)−(Ar)C−CH−CH−C−P), 129.1
(8C, 8×P−(Ar)C−CH−CH−CH), 128.8 (2C, d, 2×P−(Ar)C−CH−
CH−CH, 1JC,P = 12 Hz), 70.7−70.8 (4C, 2×Ar−(CO)−O−
(CH2)2−(CH2)2), 69.2 (2C, Ar−(CO)−O−CH2−CH2), 64.7 (2C,
Ar−(CO)−O−CH2−CH2), 53.5 (residual CH2Cl2); HRMS (ESI-
(+)-QTOF): m/z found 967.2210 [M-Cl]+ C46H44AuO7P2
+ requires
967.2228 (ppm = −1.86).
Compound 3b. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.073 g, 0.237 mmol, 1.2 equiv),
EDCI (0.057 g, 0.296 mmol, 1.5 equiv), 2b (0.150 g, 0.198 mmol, 1
equiv), and DMAP (0.012 g, 0.099 mmol, 0.5 equiv) in CH2Cl2 (5
mL). The product was isolated as a cream oil (0.185 g, 0.177 mmol,
89%); Elemental Analysis (%): calcd for C48H48AuClO8P2·
1/2CH2Cl2
C 53.46 H 4.53; found C 53.27 H 4.76; 1H NMR (CDCl3, 400 MHz):
7.90−7.92 (4H, m, 4×O−(CO)−(Ar)C−CH−CH−C−P), 7.29−
7.43 (24H, m, 4×O−(CO)−(Ar)C−CH−CH−C−P, 8×P−
(Ar)C−CH−CH−CH, 8×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−
CH−CH−CH), 4.44−4.46 (4H m, Ar−(CO)−O−CH2−CH2−
O), 3.79−3.81 (4H, m, Ar−(CO)−O−CH2−CH2−O), 3.54−3.59
(12H, m, 2×Ar−(CO)−O−(CH2)2−O−(CH2)2, Ar−(CO)−
O−((CH2)2−O)2−(CH2)2); 31P {1H} NMR (CDCl3, 162 MHz):
31.78 (1P); 13C {1H} NMR (CDCl3, 101 MHz): 165.7 (2C, 2×O−
(CO)−(Ar)C−CH−CH−C−P), 137.9 (2C, d, 2×O−(CO)−
(Ar)C−CH−CH−C−P, 1JC,P = 36 Hz), 134.0 (8C, 8×P−(Ar)C−
CH−CH−CH), 133.5 (4C, 4×O−(CO)−(Ar)C−CH−CH−C−
P), 132.1 (2C, 2×O−(CO)−(Ar)C−CH−CH−C−P), 131.4 (4C,
4×P−(Ar)C−CH−CH−CH), 130.9 (4C, d, 4×P−(Ar)C−CH−
CH−CH, 1JC,P = 40 Hz), 129.9 (4C, 4×O−(CO)−(Ar)C−CH−
CH−C−P), 129.3 (8C, 8×P−(Ar)C−CH−CH−CH), 70.7−70.8
(6C, 2×Ar−(CO)−O−(CH2)2−(CH2)2, Ar−(CO)−O−
((CH2)2−O)2−(CH2)2), 69.2 (2C, Ar−(CO)−O−CH2−CH2),
64.7 (2C, Ar−(CO)−O−CH2−CH2); HRMS (ESI(+)-QTOF):
m/z found 1011.2484 [M-Cl]+ C48H48AuO8P2
+ requires 1011.2490
(ppm = −0.59).
Compound 3c. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.082 g, 0.269 mmol, 1.2 equiv),
EDCI (0.064 g, 0.336 mmol, 1.5 equiv), 2c (0.180 g, 0.224 mmol, 1
equiv) and DMAP (0.014 g, 0.112 mmol, 0.5 equiv) in CH2Cl2 (5
mL). The product was isolated as a cream oil (0.174 g, 0.150 mmol,
62%); Elemental Analysis (%): calcd for C50H52AuClO9P2.
1/2C5H12
C 55.93 H 5.19; found C 56.14 H 5.04; 1H NMR (CDCl3, 400 MHz):
7.89−7.91 (4H, m, 4×O−(CO)−(Ar)C−CH−CH−C−P), 7.28−
7.44 (24H, m, 4×O−(CO)−(Ar)C−CH−CH−C−P, 8×P−
(Ar)C−CH−CH−CH, 8×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−
CH−CH−CH), 5.29 (s, residual CH2Cl2), 4.44−4.47 (4H m, Ar−
(CO)−O−CH2−CH2−O), 3.80−3.82 (4H, m, Ar−(CO)−O−
CH2−CH2−O), 3.59−3.68 (16H, m, 2×Ar−(CO)−O−(CH2)2−
O−(CH2)2, 2×Ar−(CO)−O−((CH2)2−O)2−(CH2)2); 31P {1H}
NMR (CDCl3, 162 MHz): 28.20 (1P);
13C {1H} NMR (CDCl3, 101
MHz): 165.9 (2C, 2×O−(CO)−(Ar)C−CH−CH−C−P), 138.6
(2C, d, 2×O−(CO)−(Ar)C−CH−CH−C−P, 1JC,P = 32 Hz),
134.1 (8C, 8×P−(Ar)C−CH−CH−CH), 133.5 (4C, 4×O−(C
O)−(Ar)C−CH−CH−C−P), 131.8 (2C, 2×O−(CO)−(Ar)C−
CH−CH−C−P), 131.5 (4C, d, 4×P−(Ar)C−CH−CH−CH, 1JC,P =
36 Hz), 131.1 (4C, 4×P−(Ar)C−CH−CH−CH), 129.8 (4C, 4×O−
(CO)−(Ar)C−CH−CH−C−P), 129.2 (8C, 8×P−(Ar)C−CH−
CH−CH), 128.8 (2C, d, 2×P−(Ar)C−CH−CH−CH, 1JC,P = 12 Hz),
70.6−70.8 (8C, 2×Ar−(CO)−O−(CH2)2−(CH2)2, 2×Ar−(C
O)−O−((CH2)2−O)2−(CH2)2), 69.2 (2C, Ar−(CO)−O−CH2−
CH2), 64.6 (2C, Ar−(CO)−O−CH2−CH2), 53.5 (residual
CH2Cl2); HRMS (ESI(+)-QTOF): m/z found 1055.2816 [M-Cl]
+
C50H52AuO9P2
+ requires 1055.2751 (ppm = 6.16).
Compound 3d. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.066 g, 0.215 mmol, 1.2 equiv),
EDCI (0.052 g, 0.269 mmol, 1.5 equiv), 2d (0.160 g, 0.180 mmol, 1
equiv), and DMAP (0.011 g, 0.090 mmol, 0.5 equiv) in CH2Cl2 (5
mL). The product was isolated as a cream oil (0.203 g, 0.172 mmol,
96%); Elemental Analysis (%): calcd for C54H60AuClO11P2 C 54.99 H
5.13; found C54.64 H 5.37; 1H NMR (CDCl3, 400 MHz): 7.90−7.92
(4H, m, 4×O−(CO)−(Ar)C−CH−CH−C−P), 7.30−7.46 (24H,
m, 4×O−(CO)−(Ar)C−CH−CH−C−P, 8×P−(Ar)C−CH−
CH−CH, 8×P−(Ar)C−CH−CH−CH, 4×P−(Ar)C−CH−CH−
CH), 5.29 (s, residual CH2Cl2),4.44−4.47 (4H m, Ar−(CO)−
O−CH2−CH2−O), 3.80−3.82 (4H, m, Ar−(CO)−O−CH2−
CH2−O), 3.59−3.70 (24H, m, 2×Ar−(CO)−O−(CH2)2−O−
(CH2)2, 2×Ar−(CO)−O−((CH2)2−O)2−(CH2)2, 2×Ar−(C
O)−O−((CH2)2−O)3−(CH2)2); 31P {1H} NMR (CDCl3, 162
MHz): 31.09 (1P); 13C {1H} NMR (CDCl3, 101 MHz): 165.7
(2C, 2×O−(CO)−(Ar)C−CH−CH−C−P), 137.8 (2C, d, 2×O−
(CO)−(Ar)C−CH−CH−C−P, 1JC,P = 36 Hz), 134.1 (8C, 8×P−
(Ar)C−CH−CH−CH), 133.5 (4C, 4×O−(CO)−(Ar)C−CH−
CH−C−P), 132.1 (2C, 2×O−(CO)−(Ar)C−CH−CH−C−P),
131.4 (4C, 4×P−(Ar)C−CH−CH−CH), 130.8 (4C, d, 4×P−
(Ar)C−CH−CH−CH, 1JC,P = 39 Hz), 129.9 (4C, 4×O−(CO)−
(Ar)C−CH−CH−C−P), 129.3 (8C, 8×P−(Ar)C−CH−CH−CH),
128.8 (2C, d, 2×P−(Ar)C−CH−CH−CH, 1JC,P = 12 Hz), 70.6−70.8
(12C, 2×Ar−(CO)−O−(CH2)2−(CH2)2, 2×Ar−(CO)−O−
((CH2)2−O)2−(CH2)2, 2×Ar−(CO)−O−((CH2)2−O)3−
(CH2)2), 69.2 (2C, Ar−(CO)−O−CH2−CH2), 64.7 (2C, Ar−
(CO)−O−CH2−CH2), 53.6 (s, residual CH2Cl2); HRMS (ESI-
(+)-QTOF): m/z found 1143.3398 [M-Cl]+ C54H60AuO11P2
+
requires 1143.3276 (ppm = 10.67), m/z found 1201.2952 [M +
Na]+ C54H60AuClO11P2Na
+ requires 1201.2863 (ppm = 7.41).
General Procedure for 4a−4d. The appropriate bis-phosphine
gold(I) complex (2 equiv) and [Ru(η6-p-cymene)Cl2]2 (1 equiv)
were dissolved in CH2Cl2 (5 mL) and stirred at rt under N2 for 42 h.
The solvent was removed via rotary evaporation, and puriﬁcation was
achieved via ﬂash column chromatography using CH2Cl2/CH3OH as
the eluent system. The product was washed with pentane (3 × 25
mL) and was isolated as an oily, red solid.
Compound 4a. According to the general procedure, 3a (0.23 g,
0.22 mmol, 2 equiv) and [Ru(η6-p-cymene)Cl2]2 (0.69 g, 0.11 mmol,
1 equiv) in CH2Cl2 (5 mL). The product was isolated as an oily, red
solid (0.064 g, 0.049 mmol, 29%); Elemental Analysis (%): calcd for
C56H58AuCl3O7P2Ru·CH2Cl2 C 49.10 H 4.34; found C 49.25 H 4.37;
1H NMR (CDCl3, 400 MHz): 8.09−8.11 (2H, m, 2×O−(CO)−
(Ar)C−CH−CH−C−P−Au), 7.89−7.93 (4H, m, 2×O−(CO)−
(Ar)C−CH−CH−C−P−Ru, 2×O−(CO)−(Ar)C−CH−CH−C−
P−Ru), 7.77−7.82 (4H, m, 4×(Ar)C−CH−CH−C−P−Ru), 7.47−
7.56 (12H, m, 2×O−(CO)−(Ar)C−CH−CH−C−P−Au,
4×(Ar)CH−CH−CH−C−P−Au, 4×(Ar)CH−CH−CH−C−P−Au,
2×(Ar)CH−CH−CH−C−P−Au), 7.37−7.41 (6H, m, 4×(Ar)CH−
CH−CH−C−P−Ru, 2×(Ar)CH−CH−CH−C−P−Ru), 5.20−5.21
(2H, d, 2×CH3−(Ar)C−CH−CH−C, 3JH,H = 6.1 Hz), 4.98−4.98
(2H, d, 2×CH3−(Ar)C−CH−CH−C, 3JH,H = 5.9 Hz), 4.45−4.48
(2H, m, Au−P−Ar−(CO)−O−CH2−CH2−O), 4.39−4.42 (2H,
m, Ru−P−Ar−(CO)−O−CH2−CH2−O), 3.74−3.81 (4H, m,
Au−P−Ar−(CO)−O−CH2−CH2−O, Ru−P−Ar−(CO)−O−
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CH2−CH2−O), 3.63−3.67 (8H, m, 2×Ar−(CO)−O−(CH2)2−
O−(CH2)2), 2.80−2.86 (1H, sept, (Ar)C−CH−CH−C−CH(CH3)2,
3JH,H = 6.9 Hz), 1.85 (3H, s, CH3−(Ar)C−CH−CH−C), 1.09−1.10
(6H, d, (Ar)C−CH−CH−C−CH(CH3)2, 3JH,H = 6.9 Hz); 31P {1H}
NMR (CDCl3, 162 MHz): 33.02 (Au−P, 1P), 25.03 (Ru−P, 1P); 13C
{1H} NMR (CDCl3, 101 MHz): 166.1 (1C, O−(CO)−(Ar)C−
CH−CH−C−P−Ru), 165.4 (1C, O−(CO)−(Ar)C−CH−CH−
C−P−Au), 139.05−139.58 (2C, m, O−(CO)−(Ar)C−CH−CH−
C−P−Ru, O−(CO)−(Ar)C−CH−CH−C−P−Au), 133.95−
134.70 (12C, m, 4×Ru−P−(Ar)C−CH−CH−CH, 4×Au−P−
(Ar)C−CH−CH−CH, 2×O−(CO)−(Ar)C−CH−CH−C−P−
Ru, 2×O−(CO)−(Ar)C−CH−CH−C−P−Au), 133.15−133.60
(3C, m, O−(CO)−(Ar)C−CH−CH−C−P−Au, 2×Ru−P−(Ar)-
C−CH−CH−CH), 132.4 (2C, d, 2×Au−P−(Ar)C−CH−CH−CH,
4JC,P = 3 Hz), 131.3 (1C, O−(CO)−(Ar)C−CH−CH−C−P−Ru),
130.7 (2C, 2×Ru−P−(Ar)C−CH−CH−CH), 130.1 (2C, 2×O−
(CO)−(Ar)C−CH−CH−C−P−Au), 129.5 (4C, d, 2×Au−P−
(Ar)C−CH−CH−CH, 3JC,P = 12 Hz), 128.7 (2C, O−(CO)−
(Ar)C−CH−CH−C−P−Ru), 128.2 (4C 2×Ru−P−(Ar)C−CH−
CH−CH), 127.8 (2C, m, 2×Au−P−(Ar)C−CH−CH−CH), 111.4
(1C, CH3−(Ar)C−CH−CH−C), 96.4 (1C, CH3−(Ar)C−CH−
CH−C), 89.1 (2C, CH3−(Ar)C−CH−CH−C), 87.4 (2C, CH3−
(Ar)C−CH−CH−C), 70.71−70.79 (4C, Ru−P−Ar−(CO)−O−
(CH2)2−O−(CH2)2, Au−P−Ar−(CO)−O−(CH2)2−O−(CH2)2),
69.2 (1C, Ru−P−Ar−(CO)−O−CH2−CH2), 69.1 (1C, Au−P−
Ar−(CO)−O−CH2−CH2), 64.7 (1C, Au−P−Ar−(CO)−O−
CH2−CH2), 64.4 (1C, Ru−P−Ar−(CO)−O−CH2−CH2), 30.4
(1C, (Ar)C−CH−CH−C−CH−(CH3)2), 22.0 (2C, (Ar)C−CH−
CH−C−CH−(CH3)2), 17.9 (1C, CH3−(Ar)C−CH−CH−C);
HRMS (ESI(+)−Orbitrap): m/z found 1331.1259 [M + Na]+
C56H58AuCl3NaO7P2Ru
+ requires 1331.1323 (ppm = −4.78).
Compound 4b. According to the general procedure, 3b (0.14 g,
0.14 mmol, 2 equiv) and [Ru(η6-p-cymene)Cl2]2 (0.043 g, 0.069
mmol, 1 equiv) in CH2Cl2 (5 mL). The product was isolated as an
oily, red solid (0.078 g, 0.058 mmol, 41%); Elemental Analysis (%):
calcd for C58H62AuCl3O8P2Ru·CH2Cl2 C 49.27 H 4.49; found C
49.19 H 4.51; 1H NMR (CDCl3, 400 MHz): 8.10−8.12 (2H, m,
2×O−(CO)−(Ar)C−CH−CH−C−P−Au), 7.90−7.95 (4H, m,
2×O−(CO)−(Ar)C−CH−CH−C−P−Ru, 2×O−(CO)−
(Ar)C−CH−CH−C−P−Ru), 7.78−7.83 (4H, m, 4×(Ar)C−CH−
CH−C−P−Ru), 7.53−7.57 (12H, m, 2×O−(CO)−(Ar)C−CH−
CH−C−P−Au, 4×(Ar)CH−CH−CH−C−P−Au, 4×(Ar)CH−CH−
CH−C−P−Au, 2×(Ar)CH−CH−CH−C−P−Au), 7.38−7.50 (6H,
m, 4×(Ar)CH−CH−CH−C−P−Ru, 2×(Ar)CH−CH−CH−C−P−
Ru), 5.21−5.22 (2H, d, 2×CH3−(Ar)C−CH−CH−C, 3JH,H = 6.2
Hz), 4.97−4.99 (2H, d, 2×CH3−(Ar)C−CH−CH-C, 3JH,H = 5.9 Hz),
4.46−4.49 (2H, m, Au−P−Ar−(CO)−O−CH2−CH2−O), 4.41−
4.43 (2H, m, Ru−P−Ar−(CO)−O−CH2−CH2−O), 3.76−3.82
(4H, m, Au−P−Ar−(CO)−O−CH2−CH2−O, Ru−P−Ar−(C
O)−O−CH2−CH2−O), 3.61−3.68 (12H, m, 2×Ar−(CO)−O−
(CH2)2−O−(CH2)2, 2×Ar−(CO)−O−((CH2)2−O)2-CH2),
2.83−2.87 (1H, sept, (Ar)C−CH−CH−C−CH(CH3)2, 3JH,H = 6.9
Hz), 1.86 (3H, s, CH3−(Ar)C−CH−CH−C), 1.10−1.12 (6H, d,
(Ar)C−CH−CH−C−CH(CH3)2, 3JH,H = 6.9 Hz); 31P {1H} NMR
(CDCl3, 162 MHz): 33.02 (Au−P, 1P), 25.00 (Ru−P, 1P); 13C {1H}
NMR (CDCl3, 101 MHz): 166.1 (1C, O−(CO)−(Ar)C−CH−
CH−C−P−Ru), 165.4 (1C, O−(CO)−(Ar)C−CH−CH−C−P−
Au), 139.09−139.61 (2C, m, O−(CO)−(Ar)C−CH−CH−C−P−
Ru, O−(CO)−(Ar)C−CH−CH−C−P−Au), 133.99−134.71
(12C, m, 4×Ru−P−(Ar)C−CH−CH−CH, 4×Au−P−(Ar)C−CH−
CH−CH, 2×O−(CO)−(Ar)C−CH−CH−C−P−Ru, 2×O−(C
O)−(Ar)C−CH−CH−C−P−Au), 133.18−133.68 (3C, m, O−(C
O)−(Ar)C−CH−CH−C−P−Au, 2×Ru−P−(Ar)-C−CH−CH−
CH), 132.4 (2C, d, 2×Au−P−(Ar)C−CH−CH−CH, 4JC,P = 3 Hz),
131.3 (1C, O−(CO)−(Ar)C−CH−CH−C−P−Ru), 130.7 (2C,
2×Ru−P−(Ar)C−CH−CH−CH), 130.1 (2C, d, 2×O−(CO)−
(Ar)C−CH−CH−C−P−Au, 3JC,P = 12 Hz), 129.6 (4C, d, 2×Au−P−
(Ar)C−CH−CH−CH, 3JC,P = 12 Hz), 128.8 (2C, O−(CO)−
(Ar)C−CH−CH−C−P−Ru), 128.3 (4C 2×Ru−P−(Ar)C−CH−
CH−CH), 127.8 (2C, m, 2×Au−P−(Ar)C−CH−CH−CH), 111.6
(1C, CH3−(Ar)C−CH−CH−C), 96.4 (1C, CH3−(Ar)C−CH−
CH−C), 89.1 (2C, CH3−(Ar)C−CH−CH−C), 87.5 (2C, CH3−
(Ar)C−CH−CH−C), 70.71−70.78 (6C, Ru−P−Ar−(CO)−O−
(CH2)2−O−(CH2)2, Au−P−Ar−(CO)−O−(CH2)2−O−(CH2)2),
Ru−P−Ar−(CO)−O−((CH2)2−O)2-CH2, Au−P−Ar−(CO)−
O−((CH2)2−O)2-CH2), 69.2 (1C, Ru−P−Ar−(CO)−O−CH2−
CH2), 69.1 (1C, Au−P−Ar−(CO)−O−CH2−CH2), 64.8 (1C,
Au−P−Ar−(CO)−O−CH2−CH2), 64.5 (1C, Ru−P−Ar−(C
O)−O−CH2−CH2), 30.4 (1C, (Ar)C−CH−CH−C−CH−(CH3)2),
22.0 (2C, (Ar)C−CH−CH−C−CH−(CH3)2), 17.9 (1C, CH3−
(Ar)C−CH−CH−C); HRMS (ESI(+)-QTOF): m/z found
1317.1989 [M − Cl]+ C58H62AuCl2O8P2Ru+ requires 1317.2017
(ppm = −2.13).
Compound 4c. According to the general procedure, 3c (0.20 g,
0.18 mmol, 2 equiv) and [Ru(η6-p-cymene)Cl2]2 (0.056 g, 0.091
mmol, 1 equiv) in CH2Cl2 (5 mL). The product was isolated as an
oily, red solid (0.036 g, 0.025 mmol, 14%); Elemental Analysis (%):
calcd for C60H66AuCl3O9P2Ru·C5H12 C 53.12 H 5.35; found C 52.96
H 5.35; 1H NMR (CDCl3, 400 MHz): 8.09−8.12 (2H, m, 2×O−
(CO)−(Ar)C−CH−CH−C−P−Au), 7.89−7.94 (4H, m, 2×O−
(CO)−(Ar)C−CH−CH−C−P−Ru, 2×O−(CO)−(Ar)C−
CH−CH−C−P−Ru), 7.78−7.82 (4H, m, 4×(Ar)C−CH−CH−C−
P−Ru), 7.52−7.59 (12H, m, 2×O−(CO)−(Ar)C−CH−CH−C−
P−Au, 4×(Ar)CH−CH−CH−C−P−Au, 4×(Ar)CH−CH−CH−C−
P−Au, 2×(Ar)CH−CH−CH−C−P−Au), 7.37−7.49 (6H, m,
4×(Ar)CH−CH−CH−C−P−Ru, 2×(Ar)CH−CH−CH−C−P−
Ru), 5.20−5.22 (2H, d, 2×CH3−(Ar)C−CH−CH−C, 3JH,H = 5.9
Hz), 4.97−4.98 (2H, d, 2×CH3−(Ar)C−CH−CH−C, 3JH,H = 5.6
Hz), 4.46−4.49 (2H, m, Au−P−Ar−(CO)−O−CH2−CH2−O),
4.40−4.43 (2H, m, Ru−P−Ar−(CO)−O−CH2−CH2−O), 3.76−
3.82 (4H, m, Au−P−Ar−(CO)−O−CH2−CH2−O, Ru−P−Ar−
(CO)−O−CH2−CH2−O), 3.58−3.68 (16H, m, 2×Ar−(CO)−
O−(CH2)2−O−(CH2)2, 2×Ar−(CO)−O−((CH2)2−O)2−
(CH2)2), 2.83−2.86 (1H, sept, (Ar)C−CH−CH−C−CH(CH3)2,
3JH,H = 6.9 Hz), 1.85 (3H, s, CH3−(Ar)C−CH−CH−C), 1.09−1.11
(6H, d, (Ar)C−CH−CH−C−CH(CH3)2, 3JH,H = 6.9 Hz); 31P {1H}
NMR (CDCl3, 162 MHz): 33.02 (Au−P, 1P), 24.99 (Ru−P, 1P); 13C
{1H} NMR (CDCl3, 101 MHz): 166.1 (1C, O−(CO)−(Ar)C−
CH−CH−C−P−Ru), 165.4 (1C, O−(CO)−(Ar)C−CH−CH−
C−P−Au), 139.15−139.58 (2C, m, O−(CO)−(Ar)C−CH−CH−
C−P−Ru, O−(CO)−(Ar)C−CH−CH−C−P−Au), 133.60−
134.67 (12C, m, 4×Ru−P−(Ar)C−CH−CH−CH, 4×Au−P−
(Ar)C−CH−CH−CH, 2×O−(CO)−(Ar)C−CH−CH−C−P−
Ru, 2×O−(CO)−(Ar)C−CH−CH−C−P−Au), 133.15−133.63
(3C, m, O−(CO)−(Ar)C−CH−CH−C−P−Au, 2×Ru−P−(Ar)-
C−CH−CH−CH), 132.4 (2C, d,2×Au−P−(Ar)C−CH−CH−CH,
4JC,P = 3 Hz), 131.3 (1C, O−(CO)−(Ar)C−CH−CH−C−P−Ru),
130.7 (2C, 2×Ru−P−(Ar)C−CH−CH−CH), 130.2 (2C, d, 2×O−
(CO)−(Ar)C−CH−CH−C−P−Au, 3JC,P = 12 Hz), 129.5 (4C, d,
2×Au−P−(Ar)C−CH−CH−CH, 3JC,P = 12 Hz), 128.8 (2C, O−
(CO)−(Ar)C−CH−CH−C−P−Ru), 128.3 (4C, d, 2×Ru−P−
(Ar)C−CH−CH−CH, 3JC,P = 10 Hz), 127.8 (2C, d, 2×Au−P−
(Ar)C−CH−CH−CH, 1JC,P = 63 Hz), 111.6 (1C, CH3−(Ar)C−
CH−CH−C), 96.4 (1C, CH3−(Ar)C−CH−CH−C), 89.1 (2C,
CH3−(Ar)C−CH−CH−C), 87.4 (2C, CH3−(Ar)C−CH−CH−C),
70.68−70.77 (8C, Ru−P−Ar−(CO)−O−(CH2)2−O−(CH2)2,
Au−P−Ar−(CO)−O−(CH2)2−O−(CH2)2), Ru−P−Ar−(C
O)−O−((CH2)2−O)2−(CH2)2 , Au−P−Ar−(CO)−O−
((CH2)2−O)2−(CH2)2), 69.2 (1C, Ru−P−Ar−(CO)−O−CH2−
CH2), 69.1 (1C, Au−P−Ar−(CO)−O−CH2−CH2), 64.8 (1C,
Au−P−Ar−(CO)−O−CH2−CH2), 64.5 (1C, Ru−P−Ar−(C
O)−O−CH2−CH2), 30.4 (1C, (Ar)C−CH−CH−C−CH−(CH3)2),
22.0 (2C, (Ar)C−CH−CH−C−CH−(CH3)2), 17.9 (1C, CH3−
(Ar)C−CH−CH−C); HRMS (ESI(+)−Orbitrap): m/z found
1419.1779 [M + Na]+ C60H66AuCl3NaO9P2Ru
+ requires 1419.1849
(ppm = −4.93).
Compound 4d. According to the general procedure, 3d (0.21 g,
0.18 mmol, 2 equiv) and [Ru(η6-p-cymene)Cl2]2 (0.056 g, 0.091
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mmol, 1 equiv) in CH2Cl2 (5 mL). The product was isolated as an
oily, red solid (0.031 g, 0.021 mmol, 11%); Elemental Analysis (%):
calcd for C64H74AuCl3O11P2Ru·CDCl3 C 48.61 H 4.77; found C
48.95 H 4.44; 1H NMR (CDCl3, 400 MHz): 8.10−8.12 (2H, m,
2×O−(CO)−(Ar)C−CH−CH−C−P−Au), 7.90−7.94 (4H, m,
2×O−(CO)−(Ar)C−CH−CH−C−P−Ru, 2×O−(CO)−
(Ar)C−CH−CH−C−P−Ru), 7.78−7.83 (4H, m, 4×(Ar)C−CH−
CH−C−P−Ru), 7.53−7.58 (12H, m, 2×O−(CO)−(Ar)C−CH−
CH−C−P−Au, 4×(Ar)CH−CH−CH−C−P−Au, 4×(Ar)CH−CH−
CH−C−P−Au, 2×(Ar)CH−CH−CH−C−P−Au), 7.38−7.50 (6H,
m, 4×(Ar)CH−CH−CH−C−P−Ru, 2×(Ar)CH−CH−CH−C−P−
Ru), 5.20−5.22 (2H, d, 2×CH3−(Ar)C−CH−CH−C, 3JH,H = 6.0
Hz), 4.97−4.99 (2H, d, 2×CH3−(Ar)C−CH−CH−C, 3JH,H = 6.3
Hz), 4.47−4.50 (2H, m, Au−P−Ar−(CO)−O−CH2−CH2−O),
4.41−4.44 (2H, m, Ru−P−Ar−(CO)−O−CH2−CH2−O), 3.77−
3.83 (4H, m, Au−P−Ar−(CO)−O−CH2−CH2−O, Ru−P−Ar−
(CO)−O−CH2−CH2−O), 3.61−3.65 (24H, m, 2×Ar−(CO)−
O−(CH2)2−O−(CH2)2, 2×Ar−(CO)−O−((CH2)2−O)2−
(CH2)2, 2×Ar−(CO)−O−((CH2)2−O)3−(CH2)2), 2.81−2.88
(1H, sept, (Ar)C−CH−CH−C−CH(CH3)2, 3JH,H = 6.9 Hz), 1.85
(3H, s, CH3−(Ar)C−CH−CH−C), 1.10−1.11 (6H, d, (Ar)C−CH−
CH−C−CH(CH3)2, 3JH,H = 6.9 Hz); 31P {1H} NMR (CDCl3, 162
MHz): 33.02 (Au−P, 1P), 24.95 (Ru−P, 1P); 13C {1H} NMR
(CDCl3, 101 MHz): 166.1 (1C, O−(CO)−(Ar)C−CH−CH−C−
P−Ru), 165.4 (1C, O−(CO)−(Ar)C−CH−CH−C−P−Au),
139.13−139.60 (2C, m, O−(CO)−(Ar)C−CH−CH−C−P−Ru,
O−(CO)−(Ar)C−CH−CH−C−P−Au), 133.98−134.68 (12C, m,
4×Ru−P−(Ar)C−CH−CH−CH, 4×Au−P−(Ar)C−CH−CH−CH,
2×O−(CO)−(Ar)C−CH−CH−C−P−Ru, 2×O−(CO)−
(Ar)C−CH−CH−C−P−Au), 133.18−133.63 (3C, m, O−(C
O)−(Ar)C−CH−CH−C−P−Au, 2×Ru−P−(Ar)-C−CH−CH−
CH), 132.4 (2C, d, 2×Au−P−(Ar)C−CH−CH−CH, 4JC,P = 3 Hz),
131.3 (1C, O−(CO)−(Ar)C−CH−CH−C−P−Ru), 130.7 (2C, d,
2×Ru−P−(Ar)C−CH−CH−CH, 4JC,P = 3 Hz), 130.2 (2C, d, 2×O−
(CO)−(Ar)C−CH−CH−C−P−Au, 3JC,P = 12 Hz), 129.5 (4C, d,
2×Au−P−(Ar)C−CH−CH−CH, 3JC,P = 12 Hz), 128.8 (2C, d, O−
(CO)−(Ar)C−CH−CH−C−P−Ru, 3JC,P = 10 Hz), 128.3 (4C, d,
2×Ru−P−(Ar)C−CH−CH−CH, 3JC,P = 10 Hz), 127.8 (2C, d,
2×Au−P−(Ar)C−CH−CH−CH, 1JC,P = 63 Hz), 111.6 (1C, CH3−
(Ar)C−CH−CH−C), 96.4 (1C, CH3−(Ar)C−CH−CH−C), 89.1
(2C, CH3−(Ar)C−CH−CH−C), 87.4 (2C, CH3−(Ar)C−CH−
CH−C), 70.65−70.77 (12C, Ru−P−Ar−(CO)−O−(CH2)2−O−
(CH2)2, Au−P−Ar−(CO)−O−(CH2)2−O−(CH2)2, Ru−P−Ar−
(CO)−O−((CH2)2−O)2−(CH2)2, Au−P−Ar−(CO)−O−
((CH2)2−O)2−(CH2)2, Ru−P−Ar−(CO)−O−((CH2)2−O)3−
(CH2)2, Au−P−Ar−(CO)−O−((CH2)2−O)3−(CH2)2), 69.2
(1C, Ru−P−Ar−(CO)−O−CH2−CH2), 69.1 (1C, Au−P−Ar−
(CO)−O−CH2−CH2), 64.8 (1C, Au−P−Ar−(CO)−O−CH2−
CH2), 64.5 (1C, Ru−P−Ar−(CO)−O−CH2−CH2), 30.4 (1C,
(Ar)C−CH−CH−C−CH−(CH3)2), 22.0 (2C, (Ar)C−CH−CH−
C−CH−(CH3)2), 17.9 (1C, CH3−(Ar)C−CH−CH−C); HRMS
(ESI(+)−Orbitrap): m/z found 1507.2302 [M + Na]+
C64H74AuCl3NaO11P2Ru
+ requires 1507.2375 (ppm = −4.80).
Cell Culture and Cytotoxicity Studies. Human ovarian carcinoma
(A2780 and A2780cisR) cell lines were obtained from the European
Collection of Cell Cultures. The human embryonic kidney (HEK-
293) cell line was obtained from ATCC (Sigma, Buchs, Switzerland).
Penicillin streptomycin, RPMI 1640 GlutaMAX (where RPMI =
Roswell Park Memorial Institute), and DMEM GlutaMAX media
(where DMEM = Dulbecco’s modiﬁed Eagle’s medium) were
obtained from Life Technologies, and fetal bovine serum (FBS) was
obtained from Sigma. The cells were cultured in RPMI 1640
GlutaMAX (A2780 and A2780cisR) and DMEM GlutaMAX (HEK-
293) media containing 10% heat-inactivated FBS and 1% penicillin−
streptomycin at 37 °C and CO2 (5%). The A2780cisR cell line was
routinely treated with cisplatin (2 μM) in the media to maintain
cisplatin resistance. The cytotoxicity was determined using the 3-(4,5-
dimethyl 2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
assay.43 Cells were seeded in ﬂat-bottomed 96-well plates as a
suspension in a prepared medium (100 μL aliquots and approximately
4300 cells/well) and preincubated for 24 h. Stock solutions of
compounds were prepared in DMSO and were rapidly diluted in a
medium. The solutions were sequentially diluted to give a ﬁnal
DMSO concentration of 0.5% and a ﬁnal compound concentration
range (0−200 μM). Cisplatin and RAPTA-C were tested as positive
(0−100 μM) and negative (200 μM) controls, respectively. The
compounds were added to the preincubated 96-well plates in 100 μL
aliquots, and the plates were incubated for a further 72 h. MTT (20
μL, 5 mg/mL in Dulbecco’s phosphate buﬀered saline) was added to
the cells, and the plates were incubated for a further 4 h. The culture
medium was aspirated, and the purple formazan crystals, formed by
the mitochondrial dehydrogenase activity of vital cells, were dissolved
in DMSO (100 μL/well). The absorbance of the resulting solutions,
directly proportional to the number of surviving cells, was quantiﬁed
at 590 nm using a SpectroMax M5e multimode microplate reader
(using SoftMax Pro software, version 6.2.2). The percentage of
surviving cells was calculated from the absorbance of wells
corresponding to the untreated control cells. The reported IC50
values are based on the means from two independent experiments,
each comprising four tests per concentration level.
Mass Spectrometry Binding Studies. Binding Studies of 4b
with L-Histidine. Complex 4b was incubated under agitation with L-
histidine for 2 h in a 1:1 complex−amino acid ratio in unbuﬀered
solution (98% Milli-Q water, 2% DMSO) at 310 K. The samples were
diluted ﬁrst in millQ water (factor 100) and then in CH3OH/
HCOOH (0.1% HCOOH in CH3OH) by a factor of 10.
Binding Studies of 4a and 4d with 1−16-mer β-Amyloid
Peptide. Complex 4a or 4d was incubated under agitation with the
16-mer β-amyloid protein for 2 h in a 1:3 complex−peptide ratio in
unbuﬀered solution (98% Milli-Q, 2% DMSO) at 310 K. The samples
were diluted ﬁrst in millQ water (factor 100) and then in CH3OH/
HCOOH (0.1% HCOOH in CH3OH) by a factor of 10.
Xevo G2-S QTOF. Routine analyses were conducted on a Xevo G2-
S QTOF mass spectrometer coupled to the Acquity UPLC Class
Binary Solvent manager and BTN sample manager (Waters,
Corporation, Milford, MA). The sample manager system temperature
was maintained at 10 °C, and the injection volume was 2 μL. Mass
spectrometer detection was operated in positive ionization using the
ZSpray dual-orthogonal multimode ESI/APCI/ESCi source. The
TOF mass spectra were acquired in the resolution mode over the
range of m/z 50−1200 at an acquisition rate of 0.036 s/spectra. The
instrument was calibrated using a solution of sodium formate (0.01
mg/L in isopropanol/H2O 90:10). A mass accuracy better than 5
ppm was achieved using a Leucine Enkephalin solution as lock-mass
(200 pg/mL in ACN/H2O (50:50)) infused continuously using the
LockSpray source. Source settings were as follows: cone, 25 V;
capillary, 3 kV, source temperature, 150 °C; desolvation temperature,
500 °C, cone gas, 10 L/h, desolvation gas, 500 L/h. Data were
processed using MassLynx 4.1 software and QuanLynx application for
quantiﬁcation.
LTQ Orbitrap FTMS. Mass spectrometry analyses were performed
on a LTQ Orbitrap FTMS instrument (LTQ Orbitrap Elite FTMS,
Thermo Scientiﬁc, Bremen, Germany) operated in the positive mode
coupled with a robotic chip-based nano-ESI source (TriVersa
Nanomate, Advion Biosciences, Ithaca, NY, United States). A
standard data acquisition and instrument control system was utilized
(Thermo Scientiﬁc), whereas the ion source was controlled by
Chipsoft 8.3.1 software (Advion BioScience). Samples were loaded
onto a 96-well plate (Eppendorf, Hamburg, Germany) within an
injection volume of 5 μL. The experimental conditions for the
ionization voltage was +1.4 kV, and the gas pressure was set at 0.30
psi. The temperature of ion transfer capillary was 275 °C and the S-
lens value was settled at 67%.. FTMS spectra were obtained in the
200−2000 m/z range in the reduced proﬁle mode with a resolution
set to 120 000. In all spectra, one microscan was acquired with a
maximum injection time value of 1000 ms. For CID, ETD and HCD
analysis, each precursor ion was isolated with a width window of 8.
Normalized collision energies for CID and HCD fragmentation were
30 and 18%, respectively. A total of 100 scans each consisting of 10
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μscans were acquired in reduced proﬁle mode and averaged. ETD
reaction time was set at 180 ms.
General Input Apm2s Parameters. Experimental MS were
exported as .txt ﬁles before being dropped into the Apm2s tool.46,51
Protons (+1 to +5), modiﬁable charge (+1 to +5), and metal adduct
(C56H58AuO7P2Ru) in the diﬀerent boxes of “List of groups”. Zone
widths were selected based of the Ru expected isotopic pattern (−6.5
to 8.5), and the common zone parameter was ﬁxed “as second”.
Minimal similarity was set at 70%, max results at 500, and best result
range at 0. b, y, and b/y (internal fragments) fragment ions were
selected for the CID experiments, whereas c, z, and c/z were chosen
for ETD.
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